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REVIEW
Abstract: The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders
that manifest as bone marrow failure with the risk of life threatening infections and bleeding.
A third of these patients may transform to acute leukemia. Age and co-morbidities have limited
treatment in the majority to supportive care with a minority of patients eligible for the only
curative modality to date, allogeneic stem cell transplantation. The advent of targeted therapy
has increased the repertoire of therapeutic options. In particular the methyl transferase inhibitor
5 Azacytidine, that targets epigenetic changes in MDS, has been shown to be effective in up
to 60% of patients in a Phase III randomized controlled trial comparing it with best supportive
care and has been licensed by the US Food and Drug Administration for use in all subtypes of
MDS. It has been shown to prolong time to leukemic transformation (21 vs 12 months with
3% transforming to leukemia p=0.0001) and is the only disease-modifying drug. Patients
with monosomy 7, trisomy 8, and diploid chromosomes appear to particularly benefit with
the former deriving sustained remissions. As an outpatient therapy, with an acceptable side
effect profile, treatment with Azacytidine needs to be considered in all MDS patients who are
eligible for treatment.
Keywords: azacytidine, myelodysplastic syndromes, demethylation, methyltransferase
inhibitor
Introduction
The myelodysplastic syndromes (MDS) are an acquired form of clonal stem cell
disorders that manifest heterogeneously but are unified clinically by progressive bone
marrow failure, susceptibility to life threatening infections, and a risk of transforming
to leukemia. Although a third of patients transform to acute myeloid leukemia (AML),
infection and bleeding are the commonest cause of morbidity and mortality (Heaney
and Golde 1999). MDS occurs with a frequency of 15–50 new cases per 100 000 per
year and this incidence appears to be increasing (Aul et al 1998) making it the
commonest hematological malignancy along with chronic lymphocytic leukemia
(CLL).
Therapeutically the management of cytopenia’s and infections predominates early
MDS. Treatment options such as AML induction type chemotherapy followed by an
allogeneic stem cell transplantation is an option for only a minority of patients, but is
the only modality that offers a cure (Ho et al 2004). In the majority of patients the
standard care is supportive in the form of blood and platelet transfusions, treatment
of infective complications and administration of growth factors such as granulocyte-
colony stimulating factor (G-CSF) and erythropoietin. There has been a dearth of
suitable therapies for the elderly that bridged the gap between the extremes of
supportive care on the one hand and stem cell transplantation on the other. The
emergence of targeted therapies has rekindled interest in their application to MDS.
Candidates have included the farnesyl transferase inhibitors, thalidomide and its
immunomodulatory drug (IMiD) analogs such as lenalidomide and the
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methyltransferase inhibitors (MTI) such as Azacytidine and
its analogue 5 Aza 2′ deoxycytidine in MDS. Potentially
reversible silencing of genes (such as CDKN2B) by promoter
methylation has been shown to occur in MDS and increase
with disease progression. The MTIs have been shown to be
demethylating agents both in vivo and in vitro and could
target these changes in MDS. The MTIs are administered
as outpatient therapies with proven efficacy. 5-Azacytidine,
in particular, has been shown to be effective in all subtypes
of MDS to prolong the time to disease progression and is
the only drug in this group that has been licensed by the US
Food and Drug Administration (FDA) for all subtypes of
MDS (Kaminskas et al 2005).
This review aims to summarize the rationale for the use
of Azacytidine and the current clinical evidence supporting
its use in the MDS.
Classification of MDS
Since the risk of leukemic transformation is varied between
various subgroups of MDS, various classification systems
and prognostic scores have attempted to identify patients
with a poor prognosis and an increased risk of leukemic
transformation. The widely used French American British
(FAB) classification of MDS identifies five morphological
subgroups of prognostic importance (Table 1) (Bennett et
al 1982). Patients with refractory anemia (RA) with excess
blasts (RAEB) and RA with excess blasts in transformation
(RAEB-t) are at a high risk of myeloid leukemic
transformation (AML) and also have a shorter median
survival whereas patients with RA and RARS (RA with
ringed sideroblasts) have a longer survival and lower
incidence of developing leukemia. The World Health
Organisation (WHO) classification of MDS identifies 7
groups (Table 2) (Vardiman 2002). Patients with RARS and
RA have only unilineage (erythroid) dysplasia with or
without 15% ringed sideroblasts respectively and experience
a protracted clinical course with median survivals of 5–6
years. The propensity for leukemic transformation is low in
both RA (7%) and RARS (1%–2%). Refractory cytopenia
with multilineage dysplasia (RCMD) and RCMD with
ringed sideroblasts are characterized by bi or pancytopenia
and dysplasia in >10% of the cells in 2 or more myeloid
cell lines. Both these groups have a shorter median survival
of approximately 33 months, and a frequency of leukemic
transformation of 10%–13%. However patients in the
RCMD group with complex karyotypes have survivals
similar to those with RAEB. The WHO classification
redefined AML as a group with bone marrow (BM) blasts
>20% and RAEB as between 5%–20% blasts with RAEB
being further classified into RAEBI (5%–9% blasts) and
RAEBII (10%–19% blasts). Approximately 21% of patients
with RAEBI and 34% of patients with RAEBII progress to
AML. The rest succumb to the effects of bone marrow
failure. The median survival is approximately 18 months
for RAEBI and 10 months for RAEBII (Germing et al 2000).
Patients with 5q- syndrome have a long survival and a low
leukemic transformation rate. The International Prognostic
Scoring System (IPSS) (Table 3) (Greenberg et al 1997)
based on bone marrow blast percentage, cytogenetics, and
number of cytopenias also identifies patients at high risk of
transformation (IPSS score 1.5). These scoring systems help
to individualize therapeutic decisions such as treatment with
chemotherapy, allogeneic transplantation, or use of drugs
like lenalidomide or methyltransferase inhibitors.
Epigenetic changes in MDS
Epigenetics is the heritable change in gene expression
without DNA sequence alteration (Bird 2002). The primary
epigenetic modifications are DNA methylation and histone
modifications, both of which are potentially reversible. DNA
methylation plays an important role in tissue and stage-
specific gene regulation (Jaenisch and Bird 2003) and
increases with age (Ahuja et al 1998). DNA
methyltransferases (DNMT) mediate methylation by
incorporating a methyl group into position 5 of the cytosine
ring resulting in 5-methyl cytosine. This modification occurs
most frequently in cytosines that precede guanosine in the
Table 1 The FAB classification of MDS
FAB subgroup Peripheral blood BM criteria
criteria
RA Blasts <1%,  Blasts < 5%, ringed
monocytes <1x10
9/L  sideroblasts <15% of
erythroblasts
RARS Blasts <1%,  Blasts<5%, ringed
monocytes < 1x10
9/L  sideroblasts >15% of
erythroblasts.
RAEB Blasts>1%, <5%,  Blasts 5%–19%
monocytes <1x10
9/L 
RAEB-t Blasts > 5% or Auer rods Blasts 20%–29% or
or Auer rods
Chronic Blasts<5%,  Blasts up to 20%,
myelomonocytic promonocytes/
leukemia monocytes often
increased.
Abbreviations: BM, bone marrow; FAB, French, American, British classification
of MDS; MDS, myelodysplastic syndromes; RA, refractory anemia; RAEB,
refractory anemia with excess blasts; RAEB-t, refractory anemia with excess
blasts in transformation; RARS, refractory anemia with ringed sideroblasts.Therapeutics and Clinical Risk Management 2006:2(4) 379
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DNA sequence called cytosine phosphodiester guanine
(CpG) dinucleotides that occur in asymmetric clusters called
CpG islands (Gardiner-Garden and Frommer 1987;
Frommer et al 1992). These islands are often associated with
the promoter regions of genes (Delgado et al 1998) and are
usually unmethylated irrespective of whether the gene is
being transcribed (Bird et al 1979). However aberrant
methylation of such promoter regions can occur in disease,
particularly cancers and correlates with gene silencing
(Antequera et al 1990). Maintenance methylation is carried
out by DNMT1 whereas de novo methylation is mediated
by DNMT 3a and 3b although these functions are not
exclusive (Okano et al 1999). Cancer is characterized by
global DNA hypomethylation and regional promoter
hypermethylation of genes. This hypermethylation occurs
in a non-random, tumor specific manner and
hypermethylation of tumor suppressor genes may act as the
second inactivating hit invoked in Knudson’s hypothesis
(Jones et al 1998). Several tumor suppressor genes such as
VHL in renal cancer (Herman et al 1994), p16
INK4A in solid
tumors and lymphomas (Esteller et al 2001; Garcia et al
2002), E-Cadherin in breast, thyroid, gastric, and colorectal
cancers (Wheeler 2005) are inactivated by promoter
hypermethylation. Promoter hypermethylation of CDKN2B
(encoding p15
INK4b) has been shown to be restricted to the
hematological malignancies (Esteller et al 2001).
Epigenetic studies in MDS
In MDS epigenetic studies to date have focused on the
methylation of cell cycle regulatory genes such as the tumor
suppressor gene CDKN2B that encodes the cyclin dependent
kinase inhibitor p15
INK4b. p15
INK4b inhibits quiescent cells
from entering the cell cycle and is important in preventing
the uncontrolled proliferation of human hemopoietic stem
cells (Dao et al 1998). Induction of p15
INK4b by cytokines
leads to myeloid progenitors being retained in G0 and
differentiating into granulocytes and macrophages
(Amanullah et al 2000; Teofili et al 2000). It is postulated
that silencing of CDKN2B by promoter methylation in MDS
leads to sustained progenitor proliferation without
differentiation resulting in peripheral cytopenias and an
excess of blasts, which are a hallmark of the disease (Drexler
1998; Cameron et al 1999).
Hypermethylation of other genes such as the calcitonin
gene occurs in 65% of MDS (Dhodapkar et al 1995). Other
genes such as HIC (Hypermethylated in cancer), E cadherin
Table 2 The WHO Classification of MDS
Disease Peripheral blood criteria BM Criteria
RA Anemia, no or rare blasts Erythroid dysplasia alone, <5% blasts, <15% ringed sideroblasts
RARS Anemia, no blasts Erythroid dysplasia alone, <5% blasts, >15% ringed sideroblasts
Refractory cytopenia with Cytopenias (bicytopenia or pancytopenia), Dysplasia in >10% of cells in >2 myeloid cell lines, <5% blasts, no
multilineage dysplasia no or rare blasts, no Auer rods, Auer rods, <15% ringed sideroblasts
<1X10
9/L monocytes
Refractory cytopenia with Cytopenias (bicytopenia or pancytopenia), Dysplasia in >10% of cells in >2 myeloid cell lines, <5% blasts, no
multilineage dysplasia and no or rare blasts, no Auer rods, Auer rods, >15% ringed sideroblasts
ringed sideroblasts <1X109/L monocytes
RAEB type1 Cytopenias, <5% blasts, no Auer rods, Unilineage or multilineage dysplasia, 5%–9% blasts, no Auer rods
<1X10
9/L monocytes
RAEB type2 Cytopenias, 5%–19% blasts, no Auer rods, Unilineage or multilineage dysplasia, 10%–19% blasts, occasional
<1X10
9/L monocytes Auer rods
MDS unclassified Cytopenias, no or rare blasts, no Auer rods Unilineage dysplasia in granulocytes or megakaryocytes, <5%
blasts, no Auer rods
MDS associated with isolated Anemia, <5% blasts, platelet count normal Normal-to-increased megakaryocytes with hypolobated nuclei,
deletion (5q) to increased <5% blasts, no Auer rods, isolated del (5q)
Abbreviations: BM, bone marrow; FAB, French, American, British classification of MDS; MDS, myelodysplastic syndromes; RA, refractory anemia; RAEB, refractory
anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; RARS, refractory anemia with ringed sideroblasts; WHO, World Health
Organisation.
Table 3 The IPSS scoring system for MDS
Prognostic Score value
variable
0 0.5 1.0 1.5 2.0
BM blasts % <5 5–10 - 11–20 21–30
Karyotype
a Good Intermediate Poor
Cytopeniasb 0 or 1 2 or 3
Note: Scores for risk groups are as follows: Low: 0, Intermediate-1: 0.5–1.0,
Intermediate-2: 1.5–2.0, High >2.5. aKarytotype: Good: normal, -Y, del(5q),
del(20q); Poor: complex (>3 abnormalities), or chromosome 7 anomalies;
Intermediate: other abnormalities; bCytopenias: defined as Hb<10g/dl, Absolute
neutrophil count <1.5x109/L and platelet count <100x10
9/L.
Abbreviations: BM, bone marrow; INT, intermediate; IPSS, International
Prognostic Scoring System; MDS, myelodysplastic syndromes.Therapeutics and Clinical Risk Management 2006:2(4) 380
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(Corn et al 2000) and ER (Estrogen Receptor) are also
hypermethylated in MDS–AML. SOCS (Suppressor of
Cytokines) methylation occurs in 31% of patients with MDS
suggesting that activation of the Janus kinase – Signal
transducer activation of transcription (JAK-STAT) pathway
plays an important role in the progression of the disease in
some patients (Johan et al 2004).
In AML numerous genes are concurrently
hypermethylated suggesting that normal DNA methylation
mechanisms are disrupted. Methylation profiling of the
calcitonin, estrogen receptor, E-Cadherin, p15, p16, Rb,
GST-Pi, and HIC1 gene promoters in AML showed that 95%
had an abnormal methylation pattern in at least one gene
whereas 75% had abnormal methylation of two or more
genes (Melki et al 1999). In AML 160 of 261 (61%) patients
(age less than 65) had estrogen receptor methylation (ERM).
ERM decreased with increasing age (p=0.0001) and was
significantly lower in patients with myelomonocytic and
monocytic AML (FAB M4/M5) (p=0.0019). ERM positive
patients had a significantly better overall survival
(p=0.0044) (Li et al 1999). Furthermore, methylation
profiling of a subset of the cases studied for ERM (36 cases
of AML) found ER to be frequently hypermethylated (47%)
as were MYOD1, PITX2, GPR37, and SDC4. Importantly
the methylation density of each of the CpG islands correlated
with ERM density suggesting the presence of a methylator
phenotype in AML (Toyota et al 2001) and a means of
identifying patients in whom demethylating therapy may
be appropriate. Rush et al (2001) further identified a
predisposition for chromosome 11 methylation, in patients
with de-novo AML. Several fold increases in DNMT1,
DNMT3a, and DNMT3b that correlated with aberrant p15
methylation also occurred in AML (Mizuno et al 2001).
However, the precise relationship between
hypermethylation of the promoters of these genes and their
contribution to the pathogenesis and progression of MDS
remains unclear except perhaps for CDKN2B.
Progression to AML occurs frequently in patients with
RAEB (28%) and RAEBt (45%) but less often in RA (10%)
and RARS (8%) (Germing et al 2000). The IPSS score
identifies chromosome abnormalities (chromosome 7 and
complex cytogenetics) and increasing blast percentage as
being important predictors of leukemic transformation.
Hypermethylation of the CDKN2B promoter appears
important in MDS evolution. p15
INK4b is upregulated during
in vitro granulocytic and megakaryocytic differentiation of
normal CD34
+ hemopoietic progenitors (Teofili et al 2001).
Deletions or mutations of CDKN2B are uncommon in MDS
(Nakamaki et al 1997). The frequency of CDKN2B
methylation is low (23%) in early MDS however its presence
at diagnosis is predictive of progressive disease and its
acquisition also accompanies disease progression (Tien et
al 2001). Furthermore CDKN2B hypermethylation occurs
frequently in RAEB, RAEBt particularly in patients with
more than 10% blasts (Quesnel et al 1998; Uchida et al
1998). The incidence of CDKN2B methylation is 58% in
chronic myelomonocytic leukemia (CMML) (Tessema et
al 2003) and 60%–75% in MDS–AML (Tien et al 2001).
Therapy related MDS (t-MDS, MDS occurring in
individuals previously treated with either cytotoxic
chemotherapy and or radiotherapy) is also accompanied by
CDKN2B promoter methylation and CpG methylation
density has both been shown to increase significantly with
advanced MDS subtypes (p=0.004 and p=0.0002) and
deletion or loss of 7q (Christiansen et al 2003). Thus
CDKN2B appears important in disease progression and in
the development of high risk MDS.
5-Azacytidine in MDS
Rationale for its use
Azacytidine is a DNMT inhibitor that has in vitro and in
vivo demethylating effects (Jones et al 1983). Since
methylation of CDKN2B occurs at a high frequency in MDS
and is acquired during disease progression, reactivation by
demethylation may halt disease progression. At high doses
Azacytidine is cytotoxic whereas at lower doses it induces
differentiation and demethylation (Christman 2002). Clinical
evidence for its efficacy in acute myeloid leukemia comes
from 8 trials involving approximately 200 patients, treated
with cytotoxic doses of Azacytidine (intravenously at doses
ranging from 60–750 mg/m2 once daily or as a repeated dose
for up to 10 days) resulting in an overall response rate of
36% (20% complete remission [CR] and 16% partial
response [PR]). These results were considerably better than
the results achieved in patients with chronic myeloid
leukemia (CML), acute lymphoblastic leukemia (ALL), and
solid tumors demonstrating the anti-leukemic activity of
Azacytidine in AML (Glover et al 1987).
Chemical structure and
pharmacokinetics of 5-Azacytidine
5-Azacytidine (Vidaza
®) is a chemically synthesized
nucleoside analogue that was manufactured in the 1960s.
Its role as a DNMT inhibitor (MTI) that can potentially
reverse pathogenic epigenetic events such as methylationTherapeutics and Clinical Risk Management 2006:2(4) 381
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of genes has led to renewed interest and enthusiasm in the
drug. 5 Azacytidine is a pyrimidine ring analogue in which
the ring carbon 5 is replaced by nitrogen (Figure 1). It is
incorporated into both RNA and DNA (Figure 2). In DNA
it binds DNMT, irreversibly leading to loss of their activity
(Creusot et al 1982; Christman 2002). Additionally DNA
cannot be methylated resulting in almost complete
demethylation of genomic DNA (Jones and Taylor 1981).
De-novo methylation is therefore inhibited, resulting in DNA
hypomethylation (Figure 3). The DNMT and Azacytidine
adducts are also toxic and mutagenic (Bhagwat and Roberts
1987). In vitro Azacytidine leads to decondensation of
chromatin, chromosomal instability, and extends the
replication time of normally late replicating heterochromatin
(reviewed in Haaf 1995).
Azacytidine is chemically unstable due to the chemical
substitution of nitrogen at position 5. This resulted in it being
manufactured as a lyophilized powder. Each single use vial
contains 100 mg of Azacytidine and 100 mg of Mannitol
that is reconstituted to 25 mg/ml in sterile water. It is stable
refrigerated for up to 8 hours but otherwise has to be
administered within an hour of preparation.
Azacytidine may be used intravenously or
subcutaneously with a similar bioavailability. It is rapidly
absorbed subcutaneously achieving a maximal concentration
within half an hour, and the concentration achieved is
proportional to the dose administered (range 10–75 mg/m
2).
It has a half-life of 1.5–2.3 hours and is undetectable 8 hours
following administration (Rudek et al 2005).
Azacytidine is phosphorylated by uridine-cytidine kinase
and is incorporated as a monophosphate into newly
synthesized RNA. It is metabolized by cytidine deaminase
resulting in the production of 5 azauridine that is mainly
eliminated by the kidneys.
Clinical trials with Azacytidine
Three successive Cancer and Leukemia Group B (CALGB)
studies culminating in the phase III randomized controlled
trial comparing 5 Azacytidine with best supportive care have
demonstrated its effectiveness (summarized in Table 4). The
dose of Azacytidine in all these studies was 75 mg/m
2. In
the first study CALGB 8421 the drug was administered
intravenously initially and later converted to subcutaneous
use, which was continued in CALGB 8921 and 9221.
CALGB 8421 was an uncontrolled phase 2 study that
enrolled patients with RAEB, RAEBt (excluded CMML)
who had not received prior radiotherapy or chemotherapy
although prior treatment with low dose cytarabine was
permitted. Patients were treated with 75 mg/m2 intravenous
(IV) continuous infusion and a dose escalation up to 150 mg/
m
2 was permitted if no response was evident by the second
cycle of treatment and no toxicity had occurred. Patients
achieving CR were treated with 3 further cycles of treatment.
Patients showing hematological improvement (HI)
continued the treatment until disease progression or relapse
was evident. 43/49 (88%) patients enrolled were evaluable,
with 5 (12%) achieving a CR, 11 (25%) PR and 5 (12%)
showed an improvement in blood counts. A median of 3.8
cycles of treatment was necessary prior to a response. This
important observation has been confirmed in trials with other
MTI and implies that at least four cycles of treatment be
administered before removing patients from this treatment
Figure 2 Incorporation of Azacytidine into RNA and its metabolite 5 Aza 2
deoxycytidine (Decitabine) into DNA.
Abbreviations: CMP,cytidine monophosphate ;CDP, Cytidine diphosphate, CTP,
Cytidine triphosphate, CR, azacytidine; dCR, decitabine; dCMP, deoxyctidine
monophosphate; dCDP, deoxycytidine diphosphate ; dCTP,deoxy cytidine
triphosphate ; DNA, deoxyribonucleic acid; RNA, ribonucleic acid.
RNA
5-Aza CTP 
5-Aza CDP 
5 Aza CR 
5 Aza-dCTP
Azacytidine 
DNA
5-Aza CMP  5 Aza-dCMP
5 Aza-dCDP Ribonucleotide 
Reductase 
5 Aza dCR
Decitabine
Figure 1 The ring structure of 5 Azacytidine and 5 Aza-2-deoxycytidine
showing substitution of N at position 5. Azacytidine is attached to a ribose
sugar whereas 5 Aza-2-deoxycytidine is attached to a deoxyribose.
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for non-response. No difference in response (survival or
median duration of remission) based on age or FAB subtype
was evident.
The CALGB 8921 was also a phase 2 study in which a
maximal permissible dose of 100 mg/m
2 was administered
subcutaneously. Sixty-seven patients were enrolled
(included CMML). Overall response was 52% with CR
observed in 12%, PR in 12% and 28% HI. In the phase
three randomized controlled trial, CALGB 9221, (Silverman
et al 2002) patients were randomized to 5 Azacytidine or a
supportive care arm. Crossover was permitted 4 months later
if the disease worsened. The patients received 5-Azacytidine
at a dosage of 75 mg/m
2/day subcutaneously for 7 days of a
28-day cycle with a minimum of four courses planned. 3
additional cycles were administered to responding patients,
whereas those with partial responses continued 5
Azacytidine till complete response or relapse. Overall
responses occurred in 60% with 7% achieving CR, 16%
PR, and 37% HI (HI). Responses of 47% were seen in the
crossover patients compared with 5% HI only in the
supportive care arm. Additionally, time to progression to
AML was significantly delayed (21 versus 12 months). After
6 months of treatment significantly less (3%) patients treated
with Azacytidine transformed to AML when compared to
those in the supportive care arm (3% vs 24%, p<0.0001).
The median duration of response was 15 months. Median
survival for patients on study for 6 months was 18 months
(from initial randomisation) compared to 14 months for
those who crossed over and 11 months for those who did
not crossover. The main side effect was worsening of
cytopenias (grade 3–4 hematological toxicity with 43%
leucopenia and 58% granulocytopenia, 52%
thrombocytopenia) although most patients recovered their
blood counts by 4 weeks. Notably no case of bone marrow
aplasia following Azacytidine occurred. Infection related
to treatment occurred in 20% of patients (Silverman et al
2002). Despite this, the responses were accompanied by an
improved quality of life (Kornblith et al 2002). Sequential
cytogenetic studies carried out on a subgroup of these
patients showed that 8% of patients with clonal cytogenetics
Table 4 CALGB Azacytidine trials
Trial 8421 Trial 8921 Trial 9221
Phase I Phase II RCT
Intravenous Subcutaneous Supportive care Azacytidine
Patient evaluated 43 68 92 99
CR 5 (12%) 8 (12%) 0 (0%) 7(7%)*
PR 11 (25%) 10 (15%) 0 (0%) 16 (16%)+
Improved 5 (12%) 18 (27%) 5 (5%) 37 (37%)
+
Total response 21 (49%) 36 (53%) 5 (5%) 60 (60%)
+
Note: *p=0.01, 
+p<0.0001
Abbreviations: CALGB, Cancer And Leukemia Group B; CR, complete response; PR, partial response, RCT, randomized controlled trial.
Figure 3 Demethylation by MTI’s. Hemimethylated DNA (mC) attracts DNMT that mediate copying of methylation onto the unmethylated sister strand once DNA
replicates. When Azacytidine is incorporated into DNA it binds DNMT irreversibly resulting in its degradation. Thus replication of methylation is prevented resulting
in passive demethylation of DNA when DNA replicates. Adapted with permission from Silverman LR, Demakos EP, Peterson BL, et al. 2002. Randomized controlled
trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol, 20:2429-40.
Abbreviations: A, adenosine; aC, azacytidine, ; DNA, deoxyribonucleic acid; DNMT, DNA methyl transferase; G, guanosine ; mC, methylated cytosine; MTI,
methyltransferase inhibitors; T, thymidine .Therapeutics and Clinical Risk Management 2006:2(4) 383
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achieved cytogenetic remissions. 13% of patients with initial
abnormal cytogenetics developed additional clones,
however 60% of patients with clonal abnormalities
developed HI despite the presence of an abnormal clone.
Additional cytogenetic abnormalities developed in those
with normal cytogenetics in 36% of patients (the same rate
as for MDS being treated with other modalities) (Najfeld et
al 2002). This study remains the only randomized controlled
study, however a confirmatory trial comparing patients with
MDS (IPSS score 1.5 or greater) treated with Azacytidine
versus conventional care or best supportive care is ongoing
and due to report in 2006.
Cytogenetics and response to
Azacytidine
Najfeld et al (2004) reported that patients with normal
cytogenetics appeared to have a superior response to
Azacytidine. Amongst 26 evaluable patients treated at King’s
College Hospital, 7 patients achieved CR. 5 of these had a
chromosome 7 abnormality and 2 a trisomy 8 (Raj et al
2005). The response rate for patients with a sole
chromosome 7 abnormality was 80% (4/5 patients treated)
and patients with monosomy 7 have durable remissions
whereas patients with Trisomy 8 experienced an early
relapse in their cytopenias. Interestingly this was not
accompanied by an increase in BM blasts. These
observations suggest that patients with chromosome 7
abnormalities may particularly benefit from Azacytidine
therapy.
Clinical response
The clinical response usually follows a typical pattern with
an increase in platelet counts being the first response.
Increases of platelet counts above 100 x10
9/L (usually 200–
700) are followed by an increase in the hemoglobin levels.
These responses are usually accompanied by a reduction in
BM blasts to less than 5%. Patients often achieve blast
reduction to less than 5% even if this is not accompanied
by an improvement in blood counts. In 8 patients BM
aspirates were carried out at Day 7 of the first cycle of
treatment and were often hypocellular with an increased
apoptosis (unpublished data). BM biopsies following
Azacytidine retain the dyplastic features of MDS despite
the normal distribution of erythroid islands and a reduction
in blasts. An increase in lymphoid follicles and lymphocytes
may occur and a marked eosinophilia is also evident (Figure
4).
Relapses following Azacytidine
Patients who relapse following complete remission are often
at a different stage of the disease at relapse (Cheson et al
2000). For example, in our cohort of patients with Trisomy
8, relapses were manifest by neutropenia, followed by
thrombocytopenia and then anemia. These relapses were
unaccompanied by an increase in BM blast percentage or
cytogenetic abnormality, however cytopenias prevented
further administration of Azacytidine then resulting in a
frank relapse at a median of 4 months after stopping therapy.
These cytopenic relapses may represent an earlier stage of
the disease ie, refractory cytopenia or a manifestation of
dysplastic relapse.
Toxicity
Myelosuppression is the commonest toxicity but is difficult
to evaluate due to antecedent cytopenias. Silverman et al
(2002) assessed myelosuppression on the relative changes
in peripheral blood counts compared with those at study
entry (Silverman et al 2002). Grade 3 toxicity was defined
as a decrease of 50%–74% whereas grade 4 constituted 75%
or greater reduction in peripheral blood counts. Grade 3 or
4 leucopenia occurs in 43%, granulocytopenia in 58%, and
thrombocytopenia in 52% of patients. Nausea or vomiting
occured in 4% and constipation (either due to the drug or
concomitant anti-emetics) occurred in 31% of patients.
Injection site erythrema/reaction is common, occurring in
27% in our experience. Rarely gout and acute renal failure
may ensue. Serum sickness like illness occurs rarely (Gryn
et al 2002). Abnormal liver function tests occur in 7% and
generalised weakness, muscle tenderness and lethargy occur
in 3% (Azacytidine Investigators brochure)
Mechanism of action in MDS
Although the various mechanisms by which the drug works
are known, definitive proof that its effects in MDS are either
due to demethylation of several key genes or to its cytotoxic
action remain unclear. Whilst CDKN2B may be an important
gene in the pathogenesis of progression of early MDS to
more aggressive phases of the disease, it is often not
hypermethylated in the CD34
+ or CD33
+ BM cells but
appears to be hypermethylated in the lymphocytes of some
patients with MDS (John et al 2005). Moreover some of the
patients who achieved CR are unmethylated at the CDKN2B
promoter suggesting demethylation of this gene is not critical
in the responses to Azacytidine in at least a subset of patients
(Issa et al 2004; Raj et al 2004).Therapeutics and Clinical Risk Management 2006:2(4) 384
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Previous studies have shown that apoptosis was
increased in early MDS (RA, RARS) but decreased with
disease progression (RAEB-t) (Parker et al 2000).
Preliminary results show that patients with high risk MDS
had low apoptosis prior to treatment that increased following
treatment with Azacytidine. Increased apoptosis correlated
with best response in patients whereas non-responders did
not show an increase in apoptosis. Therefore in advanced
MDS, reversal of the low apoptosis by Azacytidine may
cause disease regression to an earlier stage (Raj et al 2005).
Figure 4 Bone marrow responses to 5-Azacytidine. The bone marrow trephine biopsies from a patient with monosomy 7 were stained with hamatoxylin and eosin.
(A) prior to 5-Azacytidine, showing a normocellular marrow with dysplastic megakaryocytes (arrow) and no erythropoiesis. (B) Post 5-Azacytidine in cytogenetic
remission the bone marrow was normocellular and erythroid islands (arrow) were present. Marked eosinophilia post Azacytidine is evident.
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Duration of therapy
The CALGB 9221 scheduled Azacytidine for 4 cycles, if
CR was achieved a further 3 cycles were administered. For
patients showing PR/HI further courses were allowed till
either CR or relapse occurred. However relapses in
responses achieved may occur once the drug is stopped.
The median duration of response was 15 months from
randomization. The current recommendation is to use the
drug at the same schedule of dosing indefinitely once CR is
achieved. There is limited data on the precise role of
maintenance therapy. In our experience patients often
develop neutropenia accompanied by reduction in the bone
marrow cellularity that necessitates increasing the interval
between the courses of treatment. Re-treatment of 22 patients
previously treated with decitabine led to one complete
remission, 2 PR’s and 7 HI. The median duration of response
was 4 months (1–16 months) suggesting that the quality
and length of response to re-treatment was poorer than the
original response. Thus patients probably need to continue
treatment for prolonged periods of time, the dose and
scheduling being guided by BM cellularity and neutrophil
recovery
Other MTIs in MDS
Azacytidine is the prodrug for decitabine that is 10 times
more potent in inhibiting DNMT. Decitabine is incorporated
only into DNA whereas 5-Azacytidine is incorporated into
both RNA and DNA. In phase II studies, continuous infusion
of 40–50 mg/m2/day for 3 days was effective in inducing
responses in 15/29 (52%) patients with MDS. Grade III/IV
neutropenia and associated complications were common. A
multicenter phase II study of decitabine at a dosage of 45 mg/
m
2 over 3–4 hours daily for 3 days at 6 weekly intervals for
4 courses in patients who had a CR in the first two courses
or a maximum of 6 courses for partial responders. Overall
responses were higher for the IPSS high-risk group with
64% versus 49% overall. The median duration of response
was 31 weeks (Wijermans et al 2000). 19/61 (31%) patients
with cytogenetic abnormalities obtained a complete
cytogenetic response that was associated with improved
survival (Lubbert et al 2001). Low dose decitabine 5 mg/
m
2/day, 10 mg/m
2/day, 15 mg/m
2/day, or 20 mg/m
2/day
intravenously over one hour for 5/7 days a week for 2 weeks
was well tolerated with best responses observed in the 15 mg/
m
2/day (Issa et al 2004). Whilst the criteria for responses
varied in the initial trials, reanalysis of the responses of all
177 patients treated in the three European phase II studies
(median age 70 years) by the International Working Group
(IWG) criteria confirmed the efficacy of decitabine in
achieving a CR in 24% of patients and an overall response
rate of 49%. The median duration of response was 36 weeks
with a median survival of 15 months. 18% of patients
progressed to leukemia during treatment. These results are
comparable with those for 5-Azacytidine. Age, sex, FAB
subgroup, IPSS risk group, lactate dehydrogenase (LDH)
and cytogenetics were not predictive of response although
patients with high risk cytogenetics according to the IPSS
score showed a better overall survival than those with
intermediate risk abnormalities. As the IPSS score of patients
at diagnosis was not available, no comparison between
predicted survival and actual survival following decitabine
was possible to see if a particular subgroup benefited from
this therapy (Wijermans et al 2005). 61/115 patients treated
with decitabine had clonal cytogenetics and 31% of these
achieved a cytogenetic response at a median of 3 cycles of
decitabine therapy (18 weeks). The median duration of
response was 7.5 months (3–15 months). 60% (3/5) of
patients with a low IPSS score, 20% (6/30) with intermediate
risk and 38% (10/26) with high-risk cytogenetics achieved
cytogenetic remissions. These translated into a longer
survival if complete cytogenetic remission was achieved
(p=0.02) (Lubbert et al 2001). Cytogenetic remissions in
response to decitabine preceded genome wide demethylation
of genes suggesting that a cytotoxic effect or cell death of
the abnormal clone led to remissions (Mund et al 2005).
Increased platelet counts after the first course of decitabine
therapy occurred in 58% of thrombocytopenic patients and
significantly (p<0.0001) predicted overall survival (van den
Bosch et al 2004). Myelosuppression leading to fever and
sepsis occurred in 20% of patients in the phase II randomized
study with the treatment related mortality being 7%
(Wijermans et al 2000). Abnormal liver function tests were
seen in 16% of patients, grade III cardiovascular problems
occurred in 8% of patients and were mostly unrelated to
decitabine.
Combination therapy
Although the DNMT inhibitors are effective in myeloid
leukemia’s and MDS, they are limited by low response rates
(23% CR and PR) and a short median duration of response
(15 months for Azacytidine) (Silverman et al 2002).
Combination chemotherapy has led to improved CR rates
in AML. Similarly, targeting complementary biological
pathways with synergistic drugs, could improve the response
rates and duration with MTI’s.Therapeutics and Clinical Risk Management 2006:2(4) 386
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Other therapies being developed for MDS include,
histone deacetylase inhibitors (HDACi), tumour necrosis
factor (TNF) antagonists including etanercept and
infliximab, farnesyl transferase inhibitors (tipifarnib and
lonafarnib) arsenic trioxide, retinoids, lenalidomide, signal
transduction inhibitors bevacizumab, SCIO469 and
PTK787, and the glutathione S-transferase PI inhibitor
TLK199. The combination of Azacytidine with HDACi is
the furthest in clinical trials and is discussed below.
HDAC inhibitors
DNA is packaged in chromatin that is made up of an octamer
of histones. Acetylation of lysine residues on histone tails
adds a net negative charge that results in chromatin being
in an open configuration (euchromatin) whereas removal
of acetyl groups by histone deacetylases (HDAC‘s) results
in chromatin being held in a closed configuration
(heterochromatin), preventing transcription of genes.
Methylation of gene promoters acts in conjunction with
histone deacetylation in the silencing of genes. Methylated
promoters recruit transcriptional repression complexes that
include HDAC’s via specific methyl-binding proteins
leading to heterochromatin being associated with that gene.
Therefore inducing re-expression of epigenetically silenced
genes could be achieved by either demethylation of DNA
or acetylation of chromatin. In vitro studies have shown
that HDACi are unable to reactivate the expression of
heavily methylated genes. However the addition of HDACi
following exposure to DNMT inhibitors leads to synergistic
reactivation of methylated genes (Cameron et al 1999).
There are five main classes of HDAC inhibitors (reviewed
by Gore in Mufti et al 2003). Of these, Valproic acid and
MS275 in combination with MTI’s decitabine and
Azacytidine respectively are in phase I clinical trials (Gore
2005). Azacytidine combined sequentially with sodium
phenylbutyrate (a HDACi) when used at 50 mg/m
2 for 10
days (cohort A n=8), or 14 days (cohort B n=3) or 25 mg/m
2
for 14 days (n=5) followed by 375 mg/kg daily continuous
infusion of phenylbutyrate for 7 days led to clinical
responses in all three cohorts. Cohort B experienced dose
limiting toxicity of prolonged myelosuppression (greater
than 14 days) in 2/3 patients however even this cohort had
HI (1 HI-platelet and neutrophil major, and 1 HI-platelet
major). Cohort A experienced CR in 3/8 and PR in 1/8
patients whereas cohort C developed HI-neutrophil major
in 2 patients and HI-platelet major in 1 patient (Gore et
al 2004). This combination appears promising with doses
of Azacytidine equivalent to or lower than that used in
the CALGB trials. Further studies are necessary to
confirm whether the addition of HDACi result in
increased response rates and/or prolongation of
responses.
Future direction
Azacytidine induces prolonged complete remissions in up
to 25% of patients. Overall, half the patients treated derive
a clinically meaningful response in terms of transfusion
independence and or blast cell reduction. This is associated
with an improved quality of life. Patients with monosomy 7
are particularly responsive to treatment but this need
confirmation in larger trials to enable selection of patients
who would benefit maximally. Despite its universal
demethylating and cytotoxic effects some patients do not
respond. Factors responsible for this may include inadequate
plasma levels of drug. Additionally some patients achieving
CR relapse with cytopenias and identifying these patients
and the reasons for this will enable modifications in the
dosing regime and rational synergistic combination therapy
with drugs such as HDACi. The identification of target genes
and mechanisms by which the drug act are important as a
means of monitoring responses to this therapy. Azacytidine
as salvage therapy for relapsed AML with chromosome 7
abnormalities, maintenance chemotherapy for AML and in
pre-transplant conditioning regimes are areas that are being
explored in clinical trials. Epigenetic therapies such as
Azacytidine have ushered in a new era in the management
of MDS. We are at the beginning of understanding how to
optimally use this group of agents in order to achieve
maximal benefit.
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